Why the study?
Cardiovascular disease has become the leading cause of death among breast cancer survivors due to cancer therapeutics-related cardiac dysfunction from common agents like anthracyclines and HER2 inhibitors.
This review proposes a multidisciplinary stepwise approach to manage and prevent cardiovascular side effects from anthracyclines and HER2 inhibitors in breast cancer patients.
May support multidisciplinary cardiotoxicity protocols in breast cancer; leaves open prospective validation of the stepwise approach.
Cardiovascular (CV) diseases (CVD) are a major cause of long-term morbidity and mortality affecting life expectancy amongst cancer survivors. In recent years, because of the possibility of early diagnosis and the increased efficacy of neo-adjuvant and adjuvant systemic treatments (targeting specific molecular pathways), the high percentage of survival from breast cancer led CVD to become the first cause of death among survivors. Therefore, it is mandatory to adopt cardioprotective strategies to minimize CV side effects and CVD in general in breast cancer patients. Cancer therapeutics-related cardiac dysfunction (CTRCD) is a common group of side effects of chemotherapeutics widely employed in breast cancer (e.g., anthracycline and human epidermal growth factor receptor 2 inhibitors). The aim of the present manuscript is to propose a pragmatic multidisciplinary stepwise approach for prevention, early detection, and treatment of cardiotoxicity in patients with breast cancer.
No takes yet. Share an insight, caveat, or question.
Mauro et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: